semaglutide biosimilars Chinese drugmakers seek to emulate the success of Novo Nordisk's Wegovy Shingrix, oral semaglutide, biosimilars, and

The duration of GLP1 treatment was not evaluated, which matters because druginduced shedding (such as telogen effluvium) can appear 2 to 8 months after a triggering event

Alexiadou K, Hartley A, Tan TM-M, Khamis R

* Dica prtica: adicione 1 colher de sopa de chia ou psyllium no iogurte, na vitamina ou por cima das suas frutas

For everyone else, the current evidence does not support an elevated thyroid cancer risk with either medication in humans

Summary Takeaway Messages Despite the ability of GLP-1s to produce significant weight reduction and related health benefits, challenges such as GI side effects, risk of nutrient inadequacies, loss of muscle and bone mass, high costs, frequent discontinuation, and weight regain limit the use of these drugs for long-term success in individuals and populations

Its approval is specific to that indication and does not cover cosmetic or anti-aging use